

CORRECTION

Open Access



Correction: Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma

Xiaoge Gao^{1,2†}, Pin Jiang^{1,2†}, Qian Zhang^{1,2}, Qian Liu¹, Shuangshuang Jiang¹, Ling Liu¹, Maomao Guo^{1,2}, Qian Cheng^{1,2}, Junnian Zheng^{1,2*} and Hong Yao^{1,3*}

Correction: *J Exp Clin Cancer Res* 38, 362 (2019)
<https://doi.org/10.1186/s13046-019-1348-z>

Following publication of the original article [1], the authors identified an error in Fig. 9, specifically:

- Fig. 9a - the representative IHC figure of LC3B in PH1/HGFK1 + sorafenib group was repetitive to PH1/pVehicle group

The correct figure is given below.

Reference

1. Gao X, Jiang P, Zhang Q, et al. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. *J Exp Clin Cancer Res*. 2019;38:362. <https://doi.org/10.1186/s13046-019-1348-z>.

Published online: 18 April 2023

[†]Xiaoge Gao and Pin Jiang contributed equally to this work.

The original article can be found online at <https://doi.org/10.1186/s13046-019-1348-z>.

*Correspondence:

Junnian Zheng

jnzheng@xzhmu.edu.cn

Hong Yao

yaohong20055@hotmail.com

¹ Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province 221002, People's Republic of China

² Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province 221002, People's Republic of China

³ Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province 650118, People's Republic of China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 9 Effect of sorafenib and HGFK1 on the expression of LC3B, phosphorylated NF-κB, CD133, Nanog, and Oct4 in vivo. Tumor tissues from sorafenib and/or HGFK1 treated tumor-bearing mice were collected and stained with IHC. The expression of LC3B and phosphorylated NF-κB (a), as well as CD133, Nanog, and Oct4 (b) on tumor tissues was analyzed and quantified with IOD. All data shown represent the mean ± SD from three to five independent sections. Significant differences are denoted by ** for $p < 0.01$, and *** for $p < 0.001$